Healthcare leaders advocate for restoring Canada’s hypertension control program

Phar­ma’s rep­u­ta­tion is set­tling in­to a con­sis­tent “new nor­mal,” with now 45% of con­sumers re­port­ing a pos­i­tive per­cep­tion of the in­dus­try, ac­cord­ing to The Har­ris

Neu­rol­o­gists who were asked about new treat­ments for amy­otroph­ic lat­er­al scle­ro­sis (ALS) say they val­ue ef­fi­ca­cy and qual­i­ty-of-life im­prove­ments over safe­ty for drugs in de­vel­op­ment.